Pfizer’s LITFULO Shows Strong Phase 3 Results for Nonsegmental Vitiligo
Event summary
- Pfizer’s LITFULO (ritlecitinib) demonstrated significant improvements in facial and total body repigmentation in two Phase 3 trials (TRANQUILLO 2 and TRANQUILLO) for nonsegmental vitiligo.
- 21.86% of patients on 100 mg LITFULO achieved F-VASI75 compared to 2.40% on placebo; 13.02% achieved T-VASI50 vs. 2.40% on placebo.
- Pfizer plans to submit these data to regulatory authorities, including the FDA and EMA, for review.
- The safety profile of LITFULO in NSV was consistent with its established safety profile in alopecia areata, with no new safety signals observed.
The big picture
Pfizer’s LITFULO represents a potential breakthrough in treating nonsegmental vitiligo, an autoimmune disease with limited systemic treatment options. The positive Phase 3 results position LITFULO as a potential first-in-class oral therapy, addressing a significant unmet need in dermatology. Pfizer’s strategic focus on immune-mediated dermatologic conditions could expand its portfolio beyond alopecia areata, reinforcing its leadership in this therapeutic area.
What we're watching
- Regulatory Approval
- Whether the FDA and EMA will approve LITFULO for nonsegmental vitiligo based on the Phase 3 trial results.
- Market Positioning
- How LITFULO will compete in the vitiligo treatment market, given its dual mechanism targeting JAK3 and TEC family kinases.
- Commercialization Strategy
- The pace at which Pfizer can commercialize LITFULO for vitiligo, leveraging its existing approval for alopecia areata.
Related topics
